Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Pier Capital LLC

Pier Capital LLC trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 34.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 144,850 shares of the biopharmaceutical company’s stock after selling 75,597 shares during the quarter. Pier Capital LLC’s holdings in Halozyme Therapeutics were worth $8,291,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in HALO. Castleark Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $3,991,000. EP Wealth Advisors LLC acquired a new position in Halozyme Therapeutics in the third quarter worth about $357,000. Stifel Financial Corp increased its holdings in Halozyme Therapeutics by 126.3% in the third quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 9,555 shares during the last quarter. Janus Henderson Group PLC raised its stake in Halozyme Therapeutics by 6.2% during the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after buying an additional 31,871 shares in the last quarter. Finally, HighTower Advisors LLC lifted its holdings in Halozyme Therapeutics by 20.2% during the 3rd quarter. HighTower Advisors LLC now owns 36,174 shares of the biopharmaceutical company’s stock worth $2,080,000 after buying an additional 6,075 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Piper Sandler boosted their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. HC Wainwright reiterated a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. JMP Securities increased their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Stock Up 0.7 %

HALO stock opened at $48.40 on Friday. The stock has a market cap of $6.16 billion, a PE ratio of 16.03, a price-to-earnings-growth ratio of 0.44 and a beta of 1.23. The firm’s 50-day simple moving average is $52.43 and its 200 day simple moving average is $53.85. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total transaction of $620,300.00. Following the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,778,084.68. The trade was a 5.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 60,000 shares of company stock worth $3,425,000. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.